RxDoctor Payments Data

Gowri Balachandar, MD

Gastroenterology · Plano, TXNPI 1669435889

Payments from drug & device makers

$4,220in general payments, 2019–2025

Across 251 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$976
  • Vivus LLC$562
  • Pfizer$459
  • Takeda Pharmaceuticals U.S.A., Inc.$276
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$240
  • Braintree Laboratories, Inc.$215
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$4,03996%
  • Education$281%
  • Gifts$1534%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,220 in reported general payments places this provider in the 50th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$66,113
Medicare patients
297
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase66$88,614
LinzessLinaclotide66$74,019
ZenpepLipase/Protease/Amylase34$40,198
Famotidine507$10,558
Mesalamine23$10,465
Sucralfate238$5,650
Dicyclomine Hcl145$4,232
Mesalamine ErMesalamine21$4,075
Lubiprostone21$3,901
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine100$3,228
Pantoprazole Sodium305$3,184
Colestipol Hcl26$3,144
SutabSod Sulf/Pot Chloride/Mag Sulf17$2,805
Esomeprazole Magnesium41$2,545
Omeprazole169$2,541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$976$162,634132 claims
Aimmune Therapeutics, Inc.Zenpep$82$40,19834 claims
Braintree Laboratories, Inc.Sutab$215$2,80517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →